RE: Christian Ottensmeier Speaking Tonight13 Nov 2024 08:36
First consideration would be to use the best vaccine based on clinical data.
Secondary considerations would be cost, ease of manufacturing, ease of use, storage ect etc
Also who is paying/buying? If it is NHS or US insurance footing the bill then there is a process but I am guessing they will not compromise on quality. Maybe in developing countries if they cannot afford they may be able to cut a special deal or used as a demonstrator? If the second best vaccine is cheaper but nearly as effective as Ruck Rover says then I can see a market for both. Remember, even when authorsied, we do not know the long term effects and benefits of drugs. That will take decades.
Also remember that any of these vaccines such as Modi 1 or personalised vaccines if clinically successful would be world firsts... They are not going to be cheap.
Re: the professors comments surrounding costs of off the shelf. Looks like raw material costs to me